tradingkey.logo
tradingkey.logo
Search

MapLight Therapeutics Inc

MPLT
Add to Watchlist
7.250USD
+0.180+2.55%
Close 11-13 16:00(ET)
402.95MMarket Cap
LossP/E TTM

About MapLight Therapeutics Inc Company

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.

MapLight Therapeutics Inc Profile

Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -

Company Executives of MapLight Therapeutics Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Ms. Erin Pennock Foff, M.D., Ph.D.
Ms. Erin Pennock Foff, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
10.16K
-538.62%
Mr. Martin Babler
Mr. Martin Babler
Independent Director
Independent Director
7.86K
--
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
7.86K
--
Mr. Vishwas Setia
Mr. Vishwas Setia
Chief Financial Officer
Chief Financial Officer
68.00
-53486.76%
Mr. Robert Malenka, M.D., Ph.D.
Mr. Robert Malenka, M.D., Ph.D.
Director
Director
--
--
Dr. Christopher A. Kroeger, M.D.
Dr. Christopher A. Kroeger, M.D.
Co-Founder, President, Chief Executive Officer, Director
Co-Founder, President, Chief Executive Officer, Director
--
--
Mr. James Lillie, Ph.D.
Mr. James Lillie, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Kristopher L. Hanson
Mr. Kristopher L. Hanson
General Counsel
General Counsel
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Anatol Kreitzer, Ph.D.
Dr. Anatol Kreitzer, Ph.D.
Chief Discovery Officer
Chief Discovery Officer
168.68K
-7.26%
Mr. Jonathan Gillis, CPA
Mr. Jonathan Gillis, CPA
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
Interim Chief Financial Officer, Chief Administrative and Chief Accounting Officer
142.19K
-7.15%
Ms. Erin Pennock Foff, M.D., Ph.D.
Ms. Erin Pennock Foff, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
10.16K
-538.62%
Mr. Martin Babler
Mr. Martin Babler
Independent Director
Independent Director
7.86K
--
Mr. Troy M. Cox
Mr. Troy M. Cox
Independent Director
Independent Director
7.86K
--
Mr. Vishwas Setia
Mr. Vishwas Setia
Chief Financial Officer
Chief Financial Officer
68.00
-53486.76%

FAQs

Who are the top five shareholders of MapLight Therapeutics Inc?

The top five shareholders of MapLight Therapeutics Inc are: Dr. Anatol Kreitzer, Ph.D.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.